HOUSTON, November 20, 2025 — Leads & Copy — CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV), has secured a national agreement with Humana, Inc. (NYSE: HUM) to provide its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT), covering approximately 16 million people across the United States.
The agreement, effective October 29, 2025, expands the total policy coverage for the CNSide CSF TCE LDT to 67 million individuals.
The CNSide® CSF Assay Platform is designed to support rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. Clinical utility of the CNSide® has been demonstrated through peer-reviewed publications, the FORESEE clinical trial, and real-world use, according to the company.
Since 2020, more than 11,000 CNSide® tests have been conducted at over 120 U.S. cancer institutions, achieving high sensitivity (92%) and specificity (95%). The company reports that the test influences treatment decisions in 90% of cases.
The test is exclusively available through CNSide Diagnostics, LLC. as a service for healthcare professionals in the U.S.
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. develops and commercializes laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. Learn more at https://www.cnside-dx.com/.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, focused on targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), combining image-guided local beta radiation and targeted drug delivery approaches. For more information, visit https://www.plustherapeutics.com.
Humana Inc. (NYSE: HUM) is committed to putting health first for its teammates, customers, and company. Through Humana insurance services and CenterWell health care services, the company aims to facilitate better health outcomes for millions by delivering necessary care and service when needed. The company provides services to people with Medicare, Medicaid, families, individuals, and military service personnel. For more information, visit Humana.com and CenterWell.com.
This press release contains forward-looking statements regarding clinical trials, expected operations, and upcoming developments. These statements are based on assumptions and assessments made by management and are subject to risks and uncertainties.
Investor Contact:
CORE IR
investor@plustherapeutics.com
Source: Plus Therapeutics, Inc.
Source: Plus Therapeutics, Inc.
